The Meso Foundation would like to express our deepest sympathy to the family of Larry Davis. Larry was a determined warrior and untiring advocate for finding a cure for mesothelioma. He was an avid runner who used his passion for running to raise awareness and funds for mesothelioma research. He was an inspiration to all of us lucky enough to cross paths with him. We will greatly miss our dear friend, but are comforted to know that his spirit will keep on running by our side.
Adding immunotherapy to chemotherapy plus bevacizumab shows promising benefit in survival for non-epitheliod mesothelioma patients, but not across the board
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
